drugset / Trial / NCT04457726
Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19
Phase 1/2
Unknown
18 enrolled
KK Women's and Children's Hospital
Changi General Hospital · collabDuke-NUS Graduate Medical School · collabNational University Hospital, Singapore · collabSengkang General Hospital · collabSingapore General Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The overall objective of this project is to develop an emergent treatment protocol using adoptive T-cell therapy for the treatment of severe COVID-19. The central hypothesis is that SARS-CoV-2 specific T cells from convalescent donors who have recovered from COVID-19 can be manufactured expeditiously and these cells are safe and effective for the treatment of severe SARS-CoV-2 infections.
Timeline
- Start
- 2020-07-01
- Primary completion
- 2021-03
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SARS-CoV-2 Specific T Cells | Cell therapy | — | Intravenous |